# Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three trials

Source: https://onco.cc/key-papers/paper-drilon-entrectinib-ros1-lancet-oncol-2020/  
OnCo record `paper-drilon-entrectinib-ros1-lancet-oncol-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Entrectinib shrank tumours in more than three quarters of patients with ROS1-positive lung cancer and, unlike crizotinib, controlled brain metastases in most patients who had them, earning approval as a first-line option.

## Summary

Integrated analysis of 53 ROS1 inhibitor-naive patients with ROS1 fusion-positive non-small-cell lung cancer from the ALKA-372-001, STARTRK-1 and STARTRK-2 trials treated with entrectinib.

Objective response was 77 percent with median duration of response 24.6 months and median progression-free survival 19.0 months; intracranial response was 55 percent in patients with brain metastases.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: The Lancet Oncology
- Year: 2020
- DOI: 10.1016/S1470-2045(19)30690-4
- Authors: Drilon A, Siena S, Dziadziuszko R, et al.
- Findings: Objective response 77 percent; median progression-free survival 19.0 months.; Intracranial response 55 percent.
- What it means: Entrectinib is a first-line ROS1 inhibitor with brain activity, preferred over crizotinib when brain metastases are present, though repotrectinib and taletrectinib now offer longer control.
- Caveats: Single-arm pooled analysis; does not cover the G2032R resistance mutation.

## Sources

- Lancet Oncol 2020: https://doi.org/10.1016/S1470-2045(19)30690-4
- PubMed: https://pubmed.ncbi.nlm.nih.gov/31838015/

## Connected records

- cancers: [ROS1-positive non-small-cell lung cancer](https://onco.cc/cancers/ros1-positive-nsclc/)
- drugs: [Entrectinib](https://onco.cc/drugs/entrectinib/)
- journals: [The Lancet Oncology](https://onco.cc/journals/lancet-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-drilon-entrectinib-ros1-lancet-oncol-2020.json